ELVN — Enliven Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual balance sheet for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-Q	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	90.3	75.5	253	313	463
Prepaid Expenses
Total Other Current Assets
Total Current Assets	92.7	77.8	266	318	475
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	0.775	1.52	1.06	0.458	0.417
Other Long Term Assets
Total Assets	93.6	83.3	272	326	476
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	7.21	9.71	25.9	15.9	16.6
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	7.62	10.4	26	15.9	16.6
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	86	72.9	246	310	460
Total Liabilities & Shareholders' Equity	93.6	83.3	272	326	476
Total Common Shares Outstanding